MDxHealth (MDXH) investor relations material

Growth fundamentals and market opportunity

• Offers a comprehensive urology menu addressing a $4.9B U.S. market, including prostate cancer and urinary tract infection diagnostics.

• Over 500,000 patients tested, with robust clinical data and established reimbursement and guideline inclusion.

• Recent acquisitions of Genomic Prostate Score (GPS) and ExoDx Prostate Test expand the clinical pathway and commercial footprint.

• Commercial team expanded to over 80 people, leveraging a broad KOL network and established brands.

• Menu expansion and decentralization opportunities identified, including Monitor mdx for active surveillance.

Product portfolio and clinical evidence

• ExoDx Prostate Test is a non-invasive, urine-based assay with 91% NPV for clinically significant prostate cancer, included in NCCN and AUA guidelines.

• Confirm mdx is an epigenetic test with 96% NPV for aggressive prostate cancer, validated in over 55 studies and included in EAU and NCCN guidelines.

• GPS mdx analyzes gene activity to guide treatment for localized prostate cancer, validated in over 20 studies and provides risk stratification.

• Resolve mdx offers advanced molecular UTI testing, identifying pathogens and resistance genes, with results in 24-48 hours.

• Monitor mdx in development as a non-invasive surveillance tool for prostate cancer, targeting a 1.5M annual market.

Financial performance and outlook

• 2025 total revenue reached $107.9M, up 20% year-over-year, with gross profit up 26% to $69.6M and gross margin at 64.5%.

• Net loss for 2025 was $33.5M, a 12% improvement from the prior year; adjusted EBITDA improved to -$1.1M from -$14.7M.

• 2026 revenue guidance set at $137-140M, representing approximately 28% growth at the midpoint.

• Revenue growth driven by expanded menu, payer coverage, and accretive acquisitions.

• Non-IFRS measures used to evaluate operating performance, with detailed reconciliation provided.